Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ilodecakin

Drug Profile

Ilodecakin

Alternative Names: Human recombinant interleukin 10; Interleukin-10; Prevascar; rhIL-10; rIL-10; SCH-52000

Latest Information Update: 29 Jun 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Schering-Plough
  • Developer Renovo
  • Class Anti-inflammatories; Antineoplastics; Interleukins
  • Mechanism of Action Interleukin-10 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute lung injury; Autoimmune disorders; Cancer; Crohn's disease; Graft-versus-host disease; Growth disorders; Hepatic fibrosis; Hepatitis C; Herpes simplex virus infections; HIV infections; Multiple sclerosis; Myocarditis; Pancreatitis; Psoriasis; Reperfusion injury; Rheumatoid arthritis; Scars; Sepsis; Transplant rejection; Type 1 diabetes mellitus; Ulcerative colitis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 22 Jun 2018 ARMO Biosciences has been acquired by Eli Lilly
  • 06 Jun 2013 ARMO Biosciences completes acquisition of all rights to ilodecakin previously held by Renovo
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top